We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
NTRK3 kinase fusions in Spitz tumours.
- Authors
Yeh, Iwei; Tee, Meng Kian; Botton, Thomas; Shain, A Hunter; Sparatta, Alyssa J; Gagnon, Alexander; Vemula, Swapna S; Garrido, Maria C; Nakamaru, Kenji; Isoyama, Takeshi; McCalmont, Timothy H; LeBoit, Philip E; Bastian, Boris C
- Abstract
Oncogenic fusions in TRK family receptor tyrosine kinases have been identified in several cancers and can serve as therapeutic targets. We identified ETV6-NTRK3, MYO5A-NTRK3 and MYH9-NTRK3 fusions in Spitz tumours, and demonstrated that NTRK3 fusions constitutively activate the mitogen-activated protein kinase, phosphoinositide 3-kinase and phospholipase Cγ1 pathways in melanocytes. This signalling was inhibited by DS-6051a, a small-molecule inhibitor of NTRK1/2/3 and ROS1. NTRK3 fusions expand the range of oncogenic kinase fusions in melanocytic neoplasms and offer targets for a small subset of melanomas for which no targeted options currently exist. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- Publication
Journal of Pathology, 2016, Vol 240, Issue 3, p282
- ISSN
0022-3417
- Publication type
Article
- DOI
10.1002/path.4775